| Previous Close | 54.92 |
| Volume | 1,236,838 |
| Price / Earnings (Forward) | 24.59 |
| Price / Sales | 8.61 |
| Price / Book | 5.88 |
| 52 Weeks Range |
| Profit Margin | 35.27% |
| Operating Margin (TTM) | 26.29% |
| Diluted EPS (TTM) | 1.70 |
| Quarterly Revenue Growth (YOY) | 18.60% |
| Quarterly Earnings Growth (YOY) | 1.60% |
| Total Debt/Equity (MRQ) | 2.70% |
| Current Ratio (MRQ) | 5.34 |
| Operating Cash Flow (TTM) | 1.19 B |
| Levered Free Cash Flow (TTM) | 1.01 B |
| Return on Assets (TTM) | 11.54% |
| Return on Equity (TTM) | 22.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Genmab A/S | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Relative Valuation | 2.5 |
| Financial Health | 4.5 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.45 |
Select this tab to load the latest available analysis.
|
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Growth |
| % Held by Institutions | 10.31% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Paradigm Biocapital Advisors Lp | 30 Jun 2026 | 13,133,131 |
| Orbis Allan Gray Ltd | 30 Jun 2026 | 11,368,161 |
| Alliancebernstein L.P. | 30 Jun 2026 | 8,644,877 |
| Deerfield Management Company, L.P. | 30 Jun 2026 | 6,865,000 |
| Sofinnova Investments, Inc. | 30 Jun 2026 | 4,045,215 |
| Harding Loevner Lp | 30 Jun 2026 | 3,086,318 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |